Grail rises as TD Cowen more than doubles PT on FDA, Medicare optimism

** Grail GRAL.O shares rise over 2% to $140.53

** TD Cowen hikes PT on cancer test maker to $180 from $88 — implying a 31% upside to last close; keeps 'buy' rating

** Brokerage raises FDA approval chance for GRAL's Galleri early cancer-detection test to 95% from 75% after FDA advisory committee meeting, expects decision in Q127

** Expects favorable Medicare coverage decision in H128

** 5 of 12 brokerages rate GRAL "buy" or above, 7 "hold"; median PT: $120 - data compiled by LSEG

** Including session's moves, stock up ~64% YTD